期刊
NEUROLOGY
卷 78, 期 11, 页码 823-832出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e318249f6f0
关键词
-
资金
- Wellcome Trust [075491/Z/04]
- FISM Fondazione Italiana Sclerosi Multipla-Cod. [2010/B/5]
- MS Society of Australia
- UK
- Multiple Sclerosis Research Australia
- Nerve Research Foundation
- University of Sydney
- Bayer Schering Pharma
- Biogen Idec
- Merck Serono
- Novartis
- sanofi-aventis
- GW Pharma
- Ironwood
- Multiple Sclerosis Society of Canada Scientific Research Foundation
- Multiple Sclerosis Society of the United Kingdom
- Medical Research Council [G0801975] Funding Source: researchfish
- MRC [G0801975] Funding Source: UKRI
Understanding the pathogenesis of complex immunologic disorders such as multiple sclerosis (MS) is challenging. Abnormalities in many different cell types are observed in the immune system and CNS of patients with MS and the identification of the primary and secondary events is difficult. Recent studies suggest that the model of MS as a disorder mediated only by T cells is overly simplistic and propose an important role for B cells in the propagation of the disease. B-cell activation in the form of oligoclonal bands (OCB) production is the most consistent immunologic finding in patients with MS. Notably, markers of B-cell activation within the CSF of patients with MS predict conversion from clinically isolated syndrome to clinically definite MS and correlate with MRI activity, onset of relapses, and disability progression. In addition, the main genetic risk factor in MS is associated with OCB production, and environmental agents associated with MS susceptibility (vitamin D and the Epstein-Barr virus) influence B-cell proliferation and function. Finally, the only cell-specific treatments that are effective in patients with MS are monoclonal antibodies targeting the B-cell antigen CD20, suggesting a potentially causative role for B cells. Based on current evidence there is no longer doubt that B cells are relevant to the etiology and pathogenesis of MS. Elucidating the role of B cells in MS will be a fruitful strategy for disease prevention and treatment. Neurology (R) 2012;78:823-832
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据